{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:12:52Z","timestamp":1791252772202,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/cco.0b013e32835ff161","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T21:56:50Z","timestamp":1363989410000},"page":"252-260","source":"Crossref","is-referenced-by-count":33,"title":["Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer"],"prefix":"10.1097","volume":"25","author":[{"given":"Gary R.","family":"MacVicar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha H.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy.","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2010.32.8815","article-title":"Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"abstr","DOI":"10.1016\/S0923-7534(20)34329-5","article-title":"A phase 3 study of evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lanalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL Trial.","volume":"23","author":"Petrylak","year":"2012","journal-title":"Ann Oncol"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1200\/JCO.2008.20.1228","article-title":"Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.","volume":"27","author":"Sternberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer.","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"R13-8-20210128","first-page":"45154515","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SUP) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).","volume":"29","author":"Michaelson","year":"2011","journal-title":"J Clin Oncol"},{"key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy.","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"R15-8-20210128","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0923-7534(20)33503-1","article-title":"Updated survival, quality of life (QOL), and safety data of radium-223 chloride (RA-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA).","volume":"23","author":"Parker","year":"2012","journal-title":"Ann Oncol"},{"key":"R16-8-20210128","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.eururo.2009.02.016","article-title":"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.","volume":"55","author":"Calais da Silva","year":"2009","journal-title":"Eur Urol"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.urology.2010.12.043","article-title":"Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.","volume":"77","author":"Smith","year":"2011","journal-title":"Urology"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJMp048178","article-title":"Mechanisms of androgen-refractory prostate cancer.","volume":"351","author":"Debes","year":"2004","journal-title":"N Engl J Med"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"89308930","DOI":"10.1016\/S0923-7534(20)33470-0","article-title":"The impact of abiraterone acetate (AA) therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer (MCRPC).","volume":"23","author":"Basch","year":"2012","journal-title":"Ann Oncol"},{"key":"R25-8-20210128","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"R27-8-20210128","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"key":"R28-8-20210128","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1002\/cncr.27674","article-title":"Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.","volume":"118","author":"Nelson","year":"2012","journal-title":"Cancer"},{"key":"R30-8-20210128","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","article-title":"Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.","volume":"29","author":"Pili","year":"2011","journal-title":"J Clin Oncol"},{"key":"R31-8-20210128","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0923-7534(20)33525-0","article-title":"A randomized phase II study of OGX-427 plus prednisone (P) vs. P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).","volume":"23","author":"Chi","year":"2012","journal-title":"Ann Oncol"},{"key":"R32-8-20210128","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer.","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"R33-8-20210128","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"R34-8-20210128","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00262-011-1193-1","article-title":"Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.","volume":"61","author":"McNeel","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"R35-8-20210128","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.","volume":"13","author":"van den Eertwegh","year":"2012","journal-title":"Lancet Oncol"},{"key":"R36-8-20210128","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.","volume":"13","author":"Madan","year":"2012","journal-title":"Lancet Oncol"},{"key":"R37-8-20210128","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/bjc.2011.440","article-title":"Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.","volume":"105","author":"Bousquet","year":"2011","journal-title":"Br J Cancer"},{"key":"R38-8-20210128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00280-012-1914-y","article-title":"Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naive patients with metastatic castration-resistant prostate cancer.","volume":"70","author":"Mardjuadi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"R39-8-20210128","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/annonc\/mdr349","article-title":"Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 12 clinical trial.","volume":"23","author":"Zurita","year":"2012","journal-title":"Ann Oncol"},{"key":"R43-8-20210128","first-page":"412","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.","volume":"31","author":"Smith","year":"2013","journal-title":"Ann Oncol"},{"key":"R44-8-20210128","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10637-010-9573-5","article-title":"Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with nonmetastatic castration resistant prostate cancer, NCI-6735. A study by the DODPCF prostate cancer clinical trials consortium.","volume":"30","author":"Alva","year":"2012","journal-title":"Invest New Drugs"},{"key":"R45-8-20210128","doi-asserted-by":"crossref","first-page":"89708970","DOI":"10.1016\/S0923-7534(20)33492-X","article-title":"Cabozantinib (XL184) at 40mg in patients with metastatic castration resistant prostate cancer (mCRPC): Results of a phase 2 nonrandomized expansion cohort (NRE).","volume":"23","author":"de Bono","year":"2012","journal-title":"Ann Oncol"},{"key":"R47-8-20210128","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"R48-8-20210128","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":"A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone.","volume":"27","author":"Lewington","year":"1991","journal-title":"Eur J Cancer"},{"key":"R49-8-20210128","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0302-2838(03)00364-6","article-title":"Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.","volume":"44","author":"Oosterhof","year":"2003","journal-title":"Eur Urol"},{"key":"R50-8-20210128","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","article-title":"Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.","volume":"63","author":"Sartor","year":"2004","journal-title":"Urology"},{"key":"R51-8-20210128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","article-title":"A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.","volume":"48","author":"Nilsson","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e32835ff161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:39:00Z","timestamp":1621885140000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201305000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32835ff161","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}